15:00 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Resverlogix raises C$87M in private placement

On Oct. 13, Resverlogix Corp. (TSX:RVX) said Chinese API distributor Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) invested C$87 million ($69.7 million) in a private placement through the issue of 60.4 million units at C$1.44. Each...
20:16 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends fourth continuation of Phase III BETonMACE trial of apabetalone

Resverlogix Corp. (TSX:RVX) said an independent DSMB recommended for the fourth time continuation of the double-blind, placebo-controlled, international Phase III BETonMACE trial evaluating twice-daily 100 mg apabetalone (RVX000222, RVX-208) with high-dose statin therapy in patients...
20:54 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

Apabetalone: Ph III ongoing

Resverlogix said an independent DSMB recommended for the third time continuation of the double-blind, placebo-controlled, international Phase III BETonMACE trial evaluating 100 mg apabetalone twice daily with high-dose statin therapy. The company said the DSMB...
00:04 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

Apabetalone: Ph III BETonMACE ongoing

Resverlogix said an independent DSMB recommended for the second time continuation of the double-blind, placebo-controlled, international Phase III BETonMACE trial evaluating 100 mg apabetalone twice daily with high-dose statin therapy. The company said the DSMB...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

Apabetalone: Phase III ongoing

Resverlogix said a DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III BETonMACE trial evaluating 100 mg apabetalone twice daily with high-dose statin therapy. The company said the DSMB did not identify safety or...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

Apabetalone: Phase I started

Resverlogix began an open-label, New Zealand Phase I trial to evaluate single doses of 100 mg oral apabetalone in 8 healthy volunteers and 8 patients with an estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73m2...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Apabetalone: Phase III started

Resverlogix began the double-blind, placebo-controlled, international Phase III BETonMACE trial to evaluate 100 mg apabetalone twice daily with high-dose statin therapy in about 2,400 high-risk patients. Resverlogix Corp. (TSX:RVX), Calgary, Alberta   Product: Apabetalone (...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

Apabetalone: Phase III started

Resverlogix began the double-blind, placebo-controlled, international Phase III BETonMACE trial to evaluate twice-daily 100 mg RVX-208 for up to 104 weeks in about 2,400 patients on high-dose statin therapy. Shenzhen Hepalink has exclusive development and...